Paul Tudor Jones Syndax Pharmaceuticals Inc Transaction History
Tudor Investment Corp Et Al
- $26.8 Billion
- Q3 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 43,070 shares of SNDX stock, worth $719,269. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,070
Previous 47,153
8.66%
Holding current value
$719,269
Previous $968,000
14.36%
% of portfolio
0.0%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding SNDX
# of Institutions
228Shares Held
88.4MCall Options Held
1.01MPut Options Held
692K-
Black Rock Inc. New York, NY7.91MShares$132 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.84MShares$97.6 Million9.23% of portfolio
-
Wellington Management Group LLP Boston, MA4.99MShares$83.3 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$81.6 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.11MShares$68.6 Million6.25% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $945M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...